Moleculin Biotech is a biotechnology business based in the US. Moleculin Biotech shares (MBRX) are listed on the NASDAQ and all prices are listed in US Dollars. Moleculin Biotech employs 18 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.04 |
|---|---|
| 52-week range | $3.22 - $15.75 |
| 50-day moving average | $4.24 |
| 200-day moving average | $6.95 |
| Wall St. target price | $35.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-13.04 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.04 from 2024-07-22
| 1 week (2024-07-17) | -8.91% |
|---|---|
| 1 month (2024-06-24) | 11.91% |
| 3 months (2024-04-24) | -7.13% |
| 6 months (2024-01-24) | 696.53% |
| 1 year (2023-07-24) | 509.81% |
|---|---|
| 2 years (2022-07-22) | 113.76% |
| 3 years (2021-07-23) | 22.42% |
| 5 years (2019-07-24) | 6.9 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -42.66% |
| Return on equity TTM | -79.75% |
| Profit margin | 0% |
| Book value | $9.34 |
| Market Capitalization | $10 million |
TTM: trailing 12 months
We're not expecting Moleculin Biotech to pay a dividend over the next 12 months.
Moleculin Biotech's shares were split on a 1:15 basis on 21 March 2024. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Moleculin Biotech shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Moleculin Biotech shares which in turn could have impacted Moleculin Biotech's share price.
Over the last 12 months, Moleculin Biotech's shares have ranged in value from as little as $3.215 up to $15.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moleculin Biotech's is 1.836. This would suggest that Moleculin Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Moleculin Biotech, Inc. , a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. .
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.